- Home
- ROIV vs MRNA Comparison
ROIV vs MRNA Comparison
Compare ROIV & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | MRNA |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2B | 26.7B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ROIV | MRNA |
|---|---|---|
| Price | $35.36 | $60.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 12 |
| Target Price | $28.94 | ★ $34.27 |
| AVG Volume (30 Days) | 4.8M | ★ 5.0M |
| Earning Date | 05-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | $8,260,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $744.61 | $15.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $11.54 | $22.28 |
| 52 Week High | $37.00 | $85.60 |
Technical Indicators
Market Signals| Indicator | ROIV | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 50.09 |
| Support Level | $33.01 | $45.69 |
| Resistance Level | $36.35 | $59.51 |
| Average True Range (ATR) | 1.26 | 3.48 |
| MACD | 0.04 | 0.23 |
| Stochastic Oscillator | 63.92 | 74.77 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.